Thermal characterization of some polymorph solvates of the anti-inflammatory/anti-cancer sulindac

被引:9
作者
Cavallari, Cristina [1 ]
Tarterini, Fabrizio [1 ]
Fini, Adamo [1 ]
机构
[1] Univ Bologna, Dept FABIT, Via San Donato 15, I-40127 Bologna, Italy
关键词
Sulindac; Polymorph solvate; Desolvation; Decoloration; Thermal analysis; Raman spectra; QESD; FORMS;
D O I
10.1016/j.tca.2016.01.006
中图分类号
O414.1 [热力学];
学科分类号
摘要
Solvates of sulindac were obtained by crystallization from acetone, chloroform, dichloromethane and tetrahydrofuran, but not from water, methanol, ethanol and propanols, acetonitrile and ethyl acetate and were studied by thermal (differential scanning calorimetry DSC, thermogravimetry-TGA and thermomicroscopy-HSM) and spectroscopic (micro-Raman, SEM, X-EDS) analysis. It emerged from the thermal analysis that the samples thus obtained are not simple solvates or pseudo-polymorphs, but rather polymorph solvates, where the new form could be evidenced only after desolvation in controlled conditions, since the desolvation and polymorph transition processes occur together and in the thermogram the endotherms overlap. Desolvation, that is accompanied by decoloration of the sample from orange to yellow, enabled calculation of the solvate stoichiometry by the TGA parameters. The polymorph obtained from desolvation of the acetone solvate displays different thermal parameters from those obtained with chloroform, dichloromethane and tetrahydrofuran solvates. According to the solvents employed for crystallization, these thermal events leave sulindac in the form I or both I and II, outlining the very complex nature of the solid state of this drug. A new unsolvated poly morph form was directly obtained applying the technique of the quasi emulsion solvent diffusion (QESD). These results could open new perspectives in the use of the anti-inflammatory/anti-cancer sulindac in terms of formulation and mode of delivery and release. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:129 / 139
页数:11
相关论文
共 15 条
[1]  
[Anonymous], 1984, ANAL PROFILES DRUG S, DOI DOI 10.1016/S0099-5428(08)60203-8
[2]  
Byrn S. R., 1982, SOLID STATE CHEM DRU, p[8, 149]
[3]  
Cavallari C., 2013, PHARM ANAL ACTA, V4, P237
[4]   Polymorphism of sulindac: Isolation and characterization of a new polymorph and three new solvates [J].
deIlarduya, MCT ;
Martin, C ;
Goni, MM ;
MartinezOharriz, MC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (02) :248-251
[5]   Dissolution rate of polymorphs and two new pseudopolymorphs of sulindac [J].
deIlarduya, MCT ;
Martin, C ;
Goni, MM ;
MartinezUharriz, MC .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1997, 23 (11) :1095-1098
[6]  
Fini Adamo, 2010, Pharmaceutics, V2, P136
[7]   TREATMENT OF COLONIC AND RECTAL ADENOMAS WITH SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS [J].
GIARDIELLO, FM ;
HAMILTON, SR ;
KRUSH, AJ ;
PIANTADOSI, S ;
HYLIND, LM ;
CELANO, P ;
BOOKER, SV ;
ROBINSON, CR ;
OFFERHAUS, GJA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (18) :1313-1316
[8]   New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer-induced heteronucleation [J].
Grzesiak, Adam L. ;
Matzger, Adam J. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (11) :2978-2986
[9]  
Haanen C, 2001, Curr Opin Investig Drugs, V2, P677
[10]   Preface nanoparticulate systems for improved drug delivery [J].
Kawashima, Y .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (01) :1-2